Shijiazhuang Pharma Group Launches Phase III Clinical Trial of Aprocitentan Tablets for Resistant Hypertension: Seeking Participants

Jun 29, 2026 18:48 CST Updated 18:48

CSPC

Innovative Drug Research and Development, Manufacturer

Project Overview:

A multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial of Aprocitentan Tablets for the treatment of resistant hypertension, approved by the National Medical Products Administration (Approval No.: 2026LP01018) and reviewed and approved by the Ethics Committee, aims to evaluate the efficacy and safety of Aprocitentan Tablets in the treatment of resistant hypertension.

Target Population (Inclusion Criteria):

1. Age ≥ 18 years at the time of signing the ICF, with no gender restriction;

2. Received stable doses (as assessed by the investigator) of ≥3 antihypertensive agents from different pharmacological classes (one of which being a thiazide diuretic) for at least 4 weeks prior to signing the ICF, maintained until randomization, with expected dose stability during the trial; the doses shall be the maximum tolerated dose (as assessed by the investigator) or the maximum dose (according to the Chinese Guidelines for the Prevention and Treatment of Hypertension [2024 Revised Edition] or the package insert);

3. Screening period and pre-randomization SiSBP ≥140 mmHg with or without SiDBP ≥90 mmHg, and SiSBP <180 mmHg and SiDBP <110 mmHg (measured before taking background antihypertensive medications);

The above are some of the main inclusion criteria. After screening, if you are determined by the investigator to meet all the eligibility criteria, you will be formally enrolled in this study.

List of Research Centers

[Declaration]

1. This news release aims to share research recruitment information and is not intended for advertising purposes;

2. This material is for reference by healthcare professionals only; it does not constitute a basis for product recommendation and should not be regarded as medical advice.